期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌新辅助内分泌治疗 被引量：3

下载PDF
导出
摘要 为了提高对乳腺癌新辅助内分泌治疗的认识,调整传统观念,笔者回顾性阅读研究了综合文献资料,所得结论要点为:乳腺癌新辅助内分泌治疗是最近年才提出的一种治疗乳腺癌的辅助治疗手段,有助于肿瘤的降期和局部控制,且副反应较轻,临床应用前景广阔。
作者 路忠志 吴斌 时德
机构地区 四川泸州医学院附属医院普通外科 重庆医科大学附一院普通外科
出处 《中国普通外科杂志》 CAS CSCD 2007年第11期1102-1104,共3页 China Journal of General Surgery
关键词 乳腺肿瘤/治疗 辅助内分泌治疗 综述文献
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献27

  • 1Jordan VC. Tamoxifen: a most unlikely pioneering medicine [ J ] . Nat Rev Drug Discov, 2003,2 ( 3 ) : 205 -213.
  • 2Gradishar W J. Recently initiated studies : neoadjuvant treatments in next century [ J ]. Semi Oncol, 1999,26 ( 1 suppl3) :26 -29.
  • 3Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 : a unicentre randomised trial with a 124-month follow up [ J ] . Ann Oncol,1999,10(1) :47 -52.
  • 4霍彦平,高峰,吕晶.绝经后乳腺癌术前内分泌治疗的近期疗效[J].新医学,2003,34(12):736-737. 被引量：3
  • 5Holt PM, Valero V, Buzdar AU, et al. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with Severe comorbid conditions using tamoxifen as the primary therapy [ J ]. Cancer, 2000, 88 ( 9 ) : 2054 - 2060.
  • 6丁小文,郑树.乳腺癌新辅助内分泌治疗研究进展[J].国际肿瘤学杂志,2006,33(1):38-41. 被引量：12
  • 7Mauriac L, Debled M, Durand M, et al. Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinoma in early postmenopausal women [ J ]. Ann Onco1 , 2002,13 ( 1 ) : 193 - 198.
  • 8Gil Gil M J, Bamadas A, Cireral L, et al. Primary hormonal therapy with exemestane in patients with breast tumors > 3 cm in diameter : results of a Spanish muhicenter phase II trial [ J ]. Proc Am Soc Clin OnsoI, 2004,23(1) :27 -31.
  • 9Nehmat Houssami, Jack Cuzick, J Michael Dixon. The prevention, detection, and management of breast cancer [ J ]. The Medical Journal of Australia,2006,184 (5):230 - 234.
  • 10Eiermann W , Paepke S, Appfelstaedt L, et 02. Preoperative treatment of postmenopausal breast cancer patients with letmzole: a randomized double-blind multicenter study [ J ] . Ann Oncol, 2001, 12 ( 11 ) : 1527 - 1532.

二级参考文献30

  • 1Dixon JM, Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast cancer : a surgical perspective. Eur J Cancer, 2002,38 ( 17 ) :2214-2221.
  • 2Hoff PM,Valero V, Buzdar AU, et al. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer,2000,88(9):2054-2060.
  • 3Dixon JM, Love CD, Bellamy CO, et al. Izetrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat,2001,66 ( 3 ) : 191-199.
  • 4Eiermann W, Paepke S, Appfelstaedt J,et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized doable-blind multicen|er study. Ann Oncol, 2001,12 ( 11 ) : 1527-1532.
  • 5Ellis MJ, Coop A, Singh B,et. al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB- 1 and/or ErbB-2 positive, estrogen receptor positive primary breast cancer: evidence from a phase Ⅲ randomized trial. J Clin Oncol,2001,19(18) :3808-3816.
  • 6Milla Santos A, Milla L, Cairo N, et al. Anastrozole as neoadjuvant therapy for patients with hormone- dependent, locally- advanced breast cancer. Anticancer Res,2004,24 (2C) : 1315-1318.
  • 7Dixon JM, Renshaw L, Bellamy C, et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res,2000,6(6) :2229-2235.
  • 8Miller WR, Dixon JM. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control,2002,9(2 Suppl) :9-15.
  • 9Saji S, Hirose M, Toi M. Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer. Breast Cancer, 2004,11(2) :129-133.
  • 10Chow LW, Wong JL, Toi M. Celecoxib anti-aromatase neoadjuvant(CAAN) trial for locally advanced breast cancer: preliminary report. J Steroid Biochem Mol Biol, 2003,86(3-5 ) :443-447.

共引文献76

同被引文献25

  • 1江泽飞,徐兵河,宋三泰,孙燕.乳腺癌内分泌治疗的基本共识[J].中华肿瘤杂志,2006,28(3):238-239. 被引量：48
  • 2王丕琳,李玉文,尹子毅,张铁,朱强,智迎辉.表柔比星联合紫杉醇对浸润性乳腺癌新辅助化疗临床研究[J].中华肿瘤防治杂志,2007,14(9):698-700. 被引量：5
  • 3Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial [ J ]. Breast Cancer Res Treat, 2007, 105 (Suppl 1) :33 -43.
  • 4Dixon JM, Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast cancer : a surgical perspective [ J ]. Eur J Cancer, 2002, 38(17):2214-2221.
  • 5Eiermann W, Paepke S, Appfelstaedt L, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole : a randomized double- blind multicenter study [ J ]. Ann Oncol, 2001,12(11) :1505 -1506.
  • 6Smith I, Dowstt M. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive ( ER + ) operable breast cancer in postmenopausal women : the IMPACT trial ( Abstract ) [ J ] . Breast Cancer Res Treat, 2003, 82( supple 1) : S6.
  • 7Dixon JM, Love CD, Bellamy CO, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer [ J ]. Breast Cancer Res Treat, 2001 , 66 (3) :191 -199.
  • 8Ellis M J, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics [ J ]. J Natl Cancer Inst,2008,100(19) :1380-1388.
  • 9Chung HC, Rha SY, Kim JH, et al. Pglycoprotein: the intermediate end point of drug response to induction cheroot herapy in locally advanced breast cancer [ J ]. Breast Cancer Res Treat, 1997,4 (2) :65 - 72.
  • 10Bhalla K, Harris WB. Molecular and biologic determinants of neoadjuvant chemotherapy of loocoregional breast cancer [ J ] . Semin Oncol, 1998,25 ( suppl 3 ) : 19 - 24.

引证文献3

二级引证文献7

中国普通外科杂志
2007年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部